The rise of specialty and rare and orphan disease treatments, along with the increasing importance of patient-centricity, are driving the growth and heightened focus on hub services within US pharmaceutical manufacturers.
Recognising that patients suffering with rare and orphan diseases have often faced a long and arduous journey to diagnosis, the industry goal is to deliver a high-touch, comprehensive service to support patients through access, affordability and adherence challenges.
Check out the rest of the feature here
